Eli Lilly Shares Sink as New Data Shows Obesity Pill Foundayo Trailing Novo Nordisk

Prescription Data Sparks Market Share Fears

Eli Lilly (LLY) is facing a difficult Friday session, with shares dropping 2.70% while the broader S&P 500 managed a modest 0.22% gain. The primary catalyst for the nearly 3% divergence is a new report from IQVIA, a leading healthcare data provider, which showed a cooling in the momentum of Lilly’s blockbuster GLP-1 portfolio.

According to the data for the week ending April 17, 2026, total prescriptions for Lilly’s injectable weight-loss drug, Zepbound, fell approximately 2% week-over-week. In stark contrast, Novo Nordisk’s rival injectable, Wegovy, saw a 7% increase in prescriptions during the same period. This shift has reignited concerns among institutional investors that Lilly may be struggling with supply constraints or shifting physician preferences just as competition in the sector intensifies.

Foundayo’s Slow Start vs. Oral Wegovy

Perhaps more concerning for the long-term growth narrative is the early performance of Foundayo, Lilly’s newly approved oral obesity pill. The drug, which received FDA approval on April 1 and launched earlier this month, recorded just 3,707 prescriptions in its first full week on the market.

Wall Street is comparing these figures unfavorably to the January 2026 launch of Novo Nordisk’s oral Wegovy, which secured 18,410 prescriptions in its debut week. Truist analyst Srikripa Devarakonda noted that Foundayo’s initial volume represents only about 20% of what Novo’s oral offering achieved, stating that investors are likely to "scrutinize these numbers" as a sign of a slower-than-expected adoption curve for Lilly’s small-molecule strategy.

Broader Headwinds: CVS and Earnings Outlook

Adding to the downward pressure is a report that CVS Health has opted out of the Medicare obesity drug coverage model. This move is seen as a potential hurdle for market penetration, as it could limit access for a significant segment of the patient population and force Lilly to rely more heavily on higher-rebate commercial insurance channels.

Technically, the stock is testing critical support levels. Today’s move marks a deepening of a sell-off that began in March, with LLY now on track for its sixth weekly loss in the last eight weeks. The stock is currently clinging to its 200-day moving average, a level that technical analysts view as a "make-or-break" floor ahead of the company’s first-quarter earnings report.

Lilly is scheduled to report Q1 results before the market opens on Thursday, April 30. While analysts expect a 38% surge in revenue to $17.61 billion, today’s prescription data has raised the stakes. Investors will be looking for management to provide clarity on Foundayo’s rollout and whether the recent dip in Zepbound prescriptions is a temporary logistical blip or a more permanent loss of market share to Novo Nordisk.